Patients with advanced stomach and esophagus cancer who received a gut bacteria transplant from overweight or obese donors had a higher chance of keeping their cancer from growing at 12 weeks, compared to those who received their own bacteria back.
See the scientific wording
Allogenic fecal microbiota transplantation from overweight or obese donors is associated with a higher disease control rate at 12 weeks in patients with metastatic gastroesophageal cancer receiving palliative chemotherapy, compared to autologous transplantation.
Very strong evidence
Randomized trialsOne good-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman2021
This study gave cancer patients a stool transplant from an overweight healthy person or their own stool before chemo, and those who got the donor stool had their tumors stop growing or shrink more often at 12 weeks (75% vs 33%), so it supports the claim, but it's a small study and needs more research.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Doctors put stool from a healthy overweight person into the gut of cancer patients before chemotherapy. The new germs settle in and change the types of germs living in the gut. This change helps the body's immune system work better with the chemo drug to fight the cancer, so the tumors stop growing or shrink more often.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Patients with advanced stomach and esophagus cancer who received a gut bacteria transplant from overweight or obese donors had a higher chance of keeping their cancer from growing at 12 weeks, compared to those who received their own bacteria back.
Mechanism
1 studyThe treatment changes the germs in the gut, which helps the body's immune system fight cancer better when combined with chemo. The exact steps in between are not fully proven yet, but the change in germs and better tumor response have been observed.
Doctors put stool from a healthy overweight person into the gut of cancer patients before chemotherapy. The new germs settle in and change the types of germs living in the gut. This change helps the body's immune system work better with the chemo drug to fight the cancer, so the tumors stop growing or shrink more often.
Fecal microbiota transplantation introduces donor gut microorganisms into the patient's gastrointestinal tract, where they colonize and engraft, resulting in a significant shift in the composition of the gut microbial community.
The altered gut microbiota composition modulates host systemic metabolism and inflammatory pathways, leading to changes in circulating metabolites, cytokines, and immune cell activity.
These systemic changes enhance the antitumor immune response and increase the effectiveness of palliative chemotherapy, resulting in improved tumor control and a higher disease control rate.
Evidence from Studies
Supporting (1)
Community contributions welcome
This study gave cancer patients a stool transplant from an overweight healthy person or their own stool before chemo, and those who got the donor stool had their tumors stop growing or shrink more often at 12 weeks (75% vs 33%), so it supports the claim, but it's a small study and needs more research.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Fecal Microbiota Transplantation in Gastroesophageal Cancer Patients
Comprehensive search of randomized controlled trials comparing allogenic FMT from overweight/obese donors to autologous FMT in metastatic gastroesophageal cancer patients on palliative chemotherapy, with disease control rate at 12 weeks as outcome.
Double-Blind Randomized Trial of Allogenic vs Autologous FMT in Metastatic Gastroesophageal Cancer
Multicenter double-blind RCT with patients randomized to receive allogenic FMT from overweight/obese donors or autologous FMT, with disease control rate at 12 weeks as primary outcome.
Prospective Cohort Study of FMT Source and Cancer Outcomes
Prospective cohort of patients receiving FMT from overweight/obese donors vs autologous donors, matched for confounders, assessing disease control at 12 weeks.
Case-Control Study of FMT Donor Status and Disease Control
Retrospective case-control study comparing patients with vs without disease control at 12 weeks, assessing whether they received allogenic vs autologous FMT.